系统性硬化症指端溃疡的系统性药物治疗:系统文献综述
该系统文献综述检索7个数据库共4250条文献,纳入47项研究(18项随机对照试验1927例、29项前瞻性纵向观察研究661例,共2588例),评估系统性硬化症指端溃疡的系统性药物治疗证据。结果显示静脉伊洛前列素、磷酸二酯酶-5抑制剂和阿托伐他汀对活动性指端溃疡有效,波生坦可降低未来指端溃疡发生率;尚无数据支持免疫抑制或抗血小板药物用于指端溃疡管理。
要点
- 静脉伊洛前列素、磷酸二酯酶-5抑制剂和阿托伐他汀对活动性指端溃疡有效。
- 波生坦可降低未来指端溃疡发生率(2项RCT及8项OBS支持)。
- 两项小型研究提示Janus激酶抑制剂可能对活动性指端溃疡有效。
核心结论
- 有四种药物类别的多种系统性治疗对系统性硬化症指端溃疡有效。
- 缺乏稳健数据,无法确定系统性硬化症指端溃疡的最佳治疗方案。
- 现有证据质量相对较低,凸显了进一步研究的需求。
研究设计与样本
- 对7个数据库进行系统文献综述,纳入成人系统性硬化症指端溃疡患者的原始研究。
- 纳入随机对照试验(RCT)和前瞻性纵向观察研究(OBS),应用患者、干预、对照、结局框架提取数据并评估偏倚风险(RoB)。
- 因研究异质性采用叙述性总结呈现数据。
- 共纳入47项研究:18项RCT共1927例患者,29项OBS共661例患者,总计2588例,偏倚风险各异。
主要发现
- 静脉伊洛前列素、磷酸二酯酶-5抑制剂和阿托伐他汀对活动性指端溃疡有效。
- 波生坦在2项RCT(中等偏倚风险)和8项OBS(低至高等偏倚风险)中降低未来指端溃疡发生率。
- 两项小型研究(中等偏倚风险)提示Janus激酶抑制剂可能对活动性指端溃疡有效。
- 无数据支持免疫抑制或抗血小板药物用于指端溃疡管理。
关键数值与推荐
- 静脉伊洛前列素、磷酸二酯酶-5抑制剂和阿托伐他汀对活动性指端溃疡有效。
- 波生坦降低未来指端溃疡发生率(2项RCT,中等偏倚风险;8项OBS,低至高等偏倚风险)。
- Janus激酶抑制剂可能对活动性指端溃疡有效(两项小型研究,中等偏倚风险)。
- 无数据支持免疫抑制或抗血小板药物用于指端溃疡管理。
临床怎么用
- 原文未据此给出推荐。
- 作者指出有四种药物类别的多种系统性治疗对系统性硬化症指端溃疡有效,但缺乏稳健数据无法确定最佳治疗方案。
局限性
- 由于研究异质性,采用叙述性总结呈现数据。
- 缺乏稳健数据,无法确定系统性硬化症指端溃疡的最佳治疗方案。
- 现有证据质量相对较低,凸显了进一步研究的需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the evidence concerning systemic pharmacological treatments for SSc digital ulcers (DUs) to inform the development of evidence-based treatment guidelines. METHODS: A systematic literature review of seven databases was performed to identify all original research studies of adult patients with SSc DUs. Randomized controlled trials (RCTs) and prospective longitudinal observational studies (OBSs) were eligible for inclusion. Data were extracted, applying the patient, intervention, comparison, outcome framework, and risk of bias (RoB) was assessed. Due to study heterogeneity, narrative summaries were used to present data. RESULTS: Forty-seven studies that evaluated the treatment efficacy or safety of pharmacological therapies were identified among 4250 references. Data from 18 RCTs of 1927 patients and 29 OBSs of 661 patients, at various RoB (total 2588 patients) showed that i.v. iloprost, phosphodiesterase-5 inhibitors and atorvastatin are effective for the treatment of active DUs. Bosentan reduced the rate of future DUs in two RCTs (moderate RoB) and eight OBSs at low to high RoB. Two small studies (moderate RoB) indicate that Janus kinase inhibitors may be effective for the treatment of active DUs, otherwise there are no data to support the use of immunosuppression or anti-platelet agents in the management of DUs. CONCLUSION: There are several systemic treatments, across four medication classes, that are effective therapies for the management of SSc DUs. However, a lack of robust data means it is not possible to define the optimal treatment regimen for SSc DUs. The relatively low quality of evidence available has highlighted further areas of research need.
引用
- Ross L, Maltez N, Hughes M, et al. Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review. Rheumatology (Oxford). 2023. PMID: 37335850. doi:10.1093/rheumatology/kead289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。